Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View

Dr. Daniel Pollyea

Leukemia · CU Anschutz Medical Campus

View

Dr. Jessica Altman

Leukemia · Northwestern Medicine

View

Dr. Shella Saint Fleur-Lominy

Leukemia · UMSOM

View

Dr. Azra Raza

Leukemia · CUIMC

View

Dr. Molly Imgruet

Leukemia · Stanford

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    GSDr. Gary Schiller

    Dr. Gary Schiller

    Hematology & Oncology · Leukemia
    University of California, Los Angeles
    garys

    Research

    IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy

    2026

    Via Haematologica

    Research

    Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia

    2026

    Via Blood

    Research

    Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance

    2026

    Via Leuk Lymphoma

    Research

    Clinical outcomes of lentiviral vector gene therapy for sickle cell disease

    2026

    Via Blood Adv

    Research

    OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML

    2026

    Via Blood

    Research

    The case for prospective MEN1 surveillance in the era of sequential menin inhibitor therapy

    2026

    Via Leukemia

    Research

    Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model

    2026

    Via J Clin Oncol

    Research

    Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA

    2026

    Via Am J Hematol

    Research

    Tamibarotene with venetoclax and azacitidine in RARA(+) acute myeloid leukemia: results from the SY-1425-202 study

    2026

    Via Blood Neoplasia